Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Regenerative Medicines: Universal Cell Therapy Gaining Momentum
08:03am, Tuesday, 01'st Dec 2020
Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mo
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis' Product Candidate UCARTCS1 in Multiple Myeloma
08:00pm, Tuesday, 17'th Nov 2020
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-c
Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer
04:30pm, Monday, 16'th Nov 2020
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Monthly information on share capital and company voting rights
04:30pm, Friday, 06'th Nov 2020
(Article 223-16 of General Regulation of the French financial markets authority)
Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript
02:45pm, Friday, 06'th Nov 2020
Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
04:35pm, Thursday, 05'th Nov 2020
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic g
American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activity of UCART22 in BALLI-01 Phase 1 Study in R/R Adult B-ALL
09:18am, Wednesday, 04'th Nov 2020
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all
Cellectis (CLLS) Investor Presentation - Slideshow
10:54am, Friday, 11'th Sep 2020
The following slide deck was published by Cellectis S.A. in conjunction with this event..
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
01:24pm, Tuesday, 25'th Aug 2020
Over a dozen regenerative medicine drugs have been launched, generating revenues approaching $4 billion in 2019.
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020
08:30pm, Wednesday, 05'th Aug 2020
* Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patients * Enrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in r/r AML patients * MELANI-01 trial in r
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT
08:30pm, Wednesday, 29'th Jul 2020
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allo
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing
08:30pm, Tuesday, 21'st Jul 2020
NEW YORK, July 21, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.
Monthly information on share capital and company voting rights
10:04pm, Friday, 10'th Jul 2020
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, July 10, 2020 -- Listing market: Euronext Growth ISIN code: FR0010425595.
